rs16941 — BRCA1 E1038G

Common missense variant in BRCA1 with debated association to modest breast cancer risk — NOT a pathogenic BRCA1 mutation

See your personal result for BRCA1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

BRCA1 E1038G — A Common Variant, Not a Pathogenic Mutation

The BRCA1 gene is one of the most well-known genes in human genetics, encoding a large protein essential for homologous recombination DNA repair11 homologous recombination DNA repair
A high-fidelity mechanism for repairing double-strand DNA breaks using the sister chromatid as a template; BRCA1 orchestrates the assembly of the repair complex. Pathogenic mutations in BRCA1 dramatically increase lifetime risks of breast (60-70%) and ovarian (40-50%) cancer. However, not every variant in BRCA1 is pathogenic. The E1038G variant (rs16941) is a common missense polymorphism carried by roughly one-third of the global population — fundamentally different from the rare, high-penetrance BRCA1 mutations that drive clinical management decisions like prophylactic surgery.

This distinction is critical. If you carry this variant, it does not mean you have a "BRCA1 mutation" in the clinical sense. The E1038G variant has been classified as likely benign to benign by most ClinVar submitters, though a small number of association studies have reported modest risk elevations (OR ~1.1-1.3) for breast cancer. Current evidence places it in the category of a common variant with uncertain-to-modest biological significance — potentially a minor risk modifier, but not an actionable pathogenic finding.

The Mechanism

The rs16941 variant causes a glutamic acid-to-glycine substitution at position 1038 of the BRCA1 protein. This residue sits in the region between the coiled-coil domain and the BRCT repeats22 BRCT repeats
BRCA1 C-terminal domains that recognize phosphorylated proteins at DNA damage sites; critical for recruiting repair factors to double-strand breaks. The change replaces a large, negatively charged amino acid (glutamic acid) with the smallest amino acid (glycine), potentially altering local protein flexibility and interactions.

Functional studies33 Functional studies
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 comparing allele frequencies of E1038G between cancer cases and controls showed no statistically significant difference, consistent with benign status. Large-scale variant classification analyses44 variant classification analyses
Easton DF et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet, 2007 applying multifactorial likelihood methods confirmed that E1038G retains near-normal BRCA1 function and is classified as benign or likely benign — it does not break the protein.

The question is whether this common polymorphism subtly modifies BRCA1 efficiency under conditions of DNA damage stress, enough to shift population-level cancer risk by a small margin without being individually pathogenic.

The Evidence

GWAS and association studies. Large-scale genome-wide association studies have mapped the 17q21 region containing BRCA1 as harboring common breast cancer susceptibility variants. A landmark GWAS55 landmark GWAS
Easton DF et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007 established the framework for understanding how common variants in cancer-associated gene regions contribute to polygenic risk, with individual effect sizes typically in the OR 1.05-1.30 range — far below the 5-10x risk seen with pathogenic mutations.

A large-scale GWAS meta-analysis66 large-scale GWAS meta-analysis
Michailidou K et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet, 2015 of more than 120,000 individuals identified 15 new breast cancer susceptibility loci, establishing that breast cancer risk has a significant polygenic component involving many common variants of small individual effect.

Risk modification context. The EMBRACE prospective analysis77 EMBRACE prospective analysis
Mavaddat N et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst, 2013 followed BRCA1 and BRCA2 mutation carriers prospectively and estimated cumulative cancer risks, providing the quantitative risk context for understanding how common variants like E1038G differ from pathogenic BRCA1 mutations in their magnitude of effect. This underscores that common variants like E1038G are far removed from the penetrance of true BRCA1 mutations.

ClinVar consensus. The majority of ClinVar submissions classify E1038G as benign or likely benign (ClinVar variation ID 55398). The variant's high population frequency (~33% in Europeans) itself argues against pathogenicity — a truly harmful BRCA1 variant could not persist at this frequency. Some submitters note it as a variant of uncertain significance, reflecting the ambiguity of its small epidemiological signals.

Practical Implications

The key message: this variant does not warrant the clinical actions associated with pathogenic BRCA1 mutations. Prophylactic mastectomy, risk-reducing salpingo-oophorectomy, and intensive MRI surveillance protocols are for confirmed pathogenic BRCA1/2 carriers — not for carriers of this common polymorphism.

For women carrying one or two copies of the C allele, the evidence supports awareness rather than alarm. If you have additional breast cancer risk factors (family history, other genetic variants, dense breast tissue), this variant may be one small piece of a larger polygenic picture. In that context, discussing supplemental screening with your provider is reasonable.

For everyone, maintaining robust DNA repair capacity through adequate micronutrient intake is sensible. Folate, zinc, and selenium all play roles in DNA repair and genomic stability — though these are most relevant for carriers who want to optimize the DNA repair pathways this gene supports.

Interactions

The E1038G variant exists in a broader context of BRCA1 region variation. The related variant rs1799950 (BRCA1 E1038G's neighboring polymorphism) and rs11571833 (BRCA2 K3326X, a moderate-penetrance truncating variant) may combine with E1038G in polygenic risk models. Studies of polygenic risk scores for breast cancer incorporate many such common variants, and the combined effect of multiple small-effect alleles can meaningfully stratify risk across the population — even when each individual variant contributes only modestly.

The rare variant rs555607708 (BRCA1 pathogenic) represents the opposite end of the spectrum: a high-penetrance mutation that abolishes BRCA1 function. If a user carries both a common E1038G allele and a rare pathogenic BRCA1 variant on the other allele, the clinical management is driven entirely by the pathogenic mutation, not the common polymorphism.

Genotype Interpretations

What each possible genotype means for this variant.

TT Standard BRCA1 Normal

Two reference alleles — standard BRCA1 E1038 function

The TT genotype at rs16941 means both copies of your BRCA1 gene encode glutamic acid at position 1038 — the ancestral amino acid at this site. Your BRCA1 protein has full structural integrity at this position, with the negatively charged glutamic acid maintaining normal interactions in the region between the coiled-coil domain and the BRCT repeats.

It is important to understand that this result addresses only one specific position in the BRCA1 gene. The BRCA1 coding sequence spans over 5,500 nucleotides, and pathogenic mutations can occur at hundreds of different positions. A normal result at rs16941 does not rule out pathogenic BRCA1 mutations elsewhere. If you have a strong family history of breast or ovarian cancer, comprehensive BRCA1/2 sequencing (not single-SNP genotyping) is the appropriate test.

CT Heterozygous E1038G Intermediate

One copy of the E1038G variant — common BRCA1 polymorphism with uncertain modest risk modification

The TC genotype means one of your BRCA1 copies has glycine instead of glutamic acid at position 1038. Functional studies show this substitution has minimal impact on BRCA1's core DNA repair activities — unlike pathogenic mutations that abolish homologous recombination, E1038G retains near-normal function in population-frequency comparisons (Durocher et al. 1996) and large-scale variant classification studies (Easton et al. 2007).

The epidemiological picture is nuanced. Some association studies report small risk elevations (OR 1.1-1.3), while others find no significant effect. The large-scale GWAS meta-analyses of breast cancer risk have established that common variants across many loci contribute to a polygenic risk architecture, where each variant has a small individual effect but their sum can meaningfully stratify population risk.

The high carrier frequency (~44% of Europeans are heterozygous) itself argues against meaningful pathogenicity. This is a common human polymorphism, not a disease-causing mutation.

CC Homozygous E1038G Intermediate

Two copies of the E1038G variant — common BRCA1 polymorphism, not a pathogenic mutation

With two copies of the Gly1038 variant, both of your BRCA1 proteins have the amino acid substitution at position 1038. Functional assays demonstrate that E1038G retains near-normal transcriptional activation and homologous recombination capacity (Durocher et al. 1996; Easton et al. 2007), meaning your BRCA1 DNA repair function is not meaningfully impaired.

The CC genotype represents the homozygous variant state. In association studies reporting risk effects, homozygotes typically show slightly larger effect sizes than heterozygotes, consistent with a codominant model. However, the absolute magnitude remains modest (OR ~1.2-1.3 at most), and many studies fail to replicate these findings after correction for multiple testing.

This is fundamentally different from carrying two pathogenic BRCA1 mutations, which is embryonically lethal. The E1038G variant is tolerated in the homozygous state precisely because it does not significantly impair protein function. Its frequency of ~11% in European populations is orders of magnitude higher than any confirmed pathogenic BRCA1 variant.